Biotech Industry Growing Domestically and Abroad -- Oncothyreon and AEterna Zentaris Poised for Growth
March 12 2012 - 8:20AM
Marketwired
The biotechnology industry has been on an impressive run this year
as companies -- both large and small -- show impressive growth. The
iShares Nasdaq Biotechnology Index (IBB) Fund is outperforming the
broader market by a wide margin and is up more than 14 percent this
year. The Paragon Report examines investing opportunities in the
Biotechnology Industry and provides equity research on Oncothyreon
Inc. (NASDAQ: ONTY) & AEterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ). Access to the full company reports can be found at:
www.paragonreport.com/ONTY
www.paragonreport.com/AEZS
Last week, The Biotechnology Industry Organization (BIO) --
which represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and in more than 30 other nations --
applauded the U.S. House on the passage of H.R. 3606, the Jumpstart
Our Business Startups (JOBS) Act and explained the legislation's
significance on the biotech industry. According to BIO, provisions
of the Act would make the pathway to capital formation more
attainable for small biotechnology companies.
"This legislation would make capital formation easier for small
biotechnology companies, enabling them to focus more on curing and
treating disease," BIO President and CEO Jim Greenwood said in a
statement.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Larger biotech firms, meanwhile, are looking to rein in costs
and plan to outsource R&D and clinical trials and shift this
work overseas to places such as China and India, according to a
survey released by global consulting firm Booz & Company. The
study says that many biopharmaceutical companies will begin
outsourcing formerly core activities such as clinical trial
monitoring and protocol development to contract research
organizations (CROs).
According to the survey, companies are outsourcing for three
main reasons: They lack certain internal capabilities (53 percent),
they lack internal capacity (38 percent), and they need to cut
costs (44 percent).
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024